AOD-9604 Dosage Chart: 300mcg/Day Fat Loss Protocol

AOD-9604 (Advanced Obesity Drug) is a synthetic peptide fragment of human growth hormone (amino acids 176-191) that retains the fat-loss properties of GH without affecting IGF-1, insulin, or blood glucose. It has FDA GRAS status as a food ingredient. This is not medical advice.

Research-context information only. AOD-9604 is an investigational research peptide; FDA Phase 2 trial program for obesity was discontinued without approval. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.

Quick Reference: Standard Protocol

Draw volumes reflect community-documented reconstitution protocols, not a recommended dosing schedule.

The protocol below reflects the most commonly documented community approach.

Standard protocol: 300 mcg SC injection into abdominal fat, first thing in the morning on an empty stomach. 5 days on, 2 days off. Community protocols describe waiting 20–30 minutes before eating.

Cycling: 8 Weeks On, 8 Weeks Off

Run 300 mcg daily (5 on / 2 off) for 8 weeks, then take 8 weeks off. Community protocols use the 8-week on/off structure to reduce the risk of receptor desensitization — this hasn't been directly tested in published AOD-9604 trials.

Weeks 1-2: Some users start at 250 mcg daily to assess tolerance. AOD-9604 is generally well-tolerated with minimal side effects.

Weeks 3-8: 300 mcg daily, 5 days on / 2 days off.

Timing matters: Community protocols describe fasted morning injection; the cited rationale is avoiding insulin spikes that may compete with lipolytic signaling. Some users inject 30 minutes before cardio for enhanced fat oxidation.

Enhanced Protocol (Community)

Some community protocols push doses higher for more aggressive fat loss:

The 300 mcg standard community protocol is the recommended starting point. 500 mcg is the upper end referenced in community discussions.

Routes of Administration

Subcutaneous injection (primary): Community protocols describe subcutaneous injection into abdominal fat, love handles, or thighs, typically 0.1–0.3 mL with an insulin syringe (29–31 gauge).

Oral (research context): Animal studies showed oral activity at 500 mcg/kg, and AOD-9604 has GRAS status as a food ingredient. Community preference remains injectable for more reliable bioavailability.

Intra-articular (emerging): Recent research explored AOD-9604 for joint health, with cartilage-protective effects observed in animal models.

Reconstitution Quick Reference

Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. For 300 mcg: 300 / 2,500 = 0.12 mL = ~11 units. One vial lasts ~16 doses.

Community protocols describe gentle swirling — not shaking — to avoid degradation, with storage at 2–8°C and use within 28 days. For step-by-step instructions, see the Reconstitution Calculator.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

AOD-9604 has a notable research history including animal studies, human clinical trials, and FDA GRAS evaluation.

Animal studies: Both hGH and AOD-9604 reduced body weight gain via increased fat oxidation and plasma glycerol levels without affecting IGF-1 or insulin (Ng et al., 2001). AOD-9604 stimulates lipolysis through beta-3 adrenergic receptor pathways (Heffernan et al., 2001). Oral doses of 500 mcg/kg reduced body weight gain in Zucker rats without affecting lean mass or blood glucose (Ng et al., 2000).

Human clinical context: AOD-9604 progressed through Phase 2 trials. Safety was confirmed with no significant adverse events. Efficacy was mixed -- weight loss observed in initial trials but not replicated in later studies that included intensive diet/exercise programs. No effects on IGF-1, insulin, or glucose were confirmed in humans.

Joint health: Intra-articular AOD-9604 enhanced cartilage regeneration in rabbit OA models, with combined AOD-9604 + hyaluronic acid outperforming either alone (Kwon & Park, 2015).

Stacking AOD-9604

Stacking tips: Community stacking protocols describe maintaining fasted morning timing for AOD-9604 and moving GH secretagogues to nighttime. Diet remains critical -- the lipolytic activity documented in animal trials targets fat loss but doesn't replace a caloric deficit.

Side Effects & Safety

• GRAS status -- FDA Generally Recognized As Safe as a food ingredient
• No GH axis effects -- does not alter IGF-1, insulin, or glucose levels
• Injection site redness -- mild, standard for SC peptides
• Mild headache -- infrequent
• Slight stomach upset -- if injected too close to eating
• Water retention -- rare, unlike full GH
• No diabetogenic effects -- blood sugar neutral, no acromegaly risk

AOD-9604 has one of the cleanest safety profiles in the peptide space due to its GH fragment design. For more detail, see our AOD-9604 benefits guide.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once AOD-9604 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 5 mg vial + 2 mL BAC water (2.5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 5 mg vial + 3 mL BAC water (1.67 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.